Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice
Scientific relevance. A promising option for dysbiosis correction is the use of metabiotics, products based on metabolites of probiotic microorganisms. During fermentation, Bacillus subtilis bacteria (strains 3H and 1719) produce metabolites that exhibit probiotic properties in vitro. These observat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2023-10-01
|
| Series: | Биопрепараты: Профилактика, диагностика, лечение |
| Subjects: | |
| Online Access: | https://www.biopreparations.ru/jour/article/view/445 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839581789579902976 |
|---|---|
| author | S. А. Lazarev N. O. Vartanova A. V. Poddubikov N. A. Mikhailova |
| author_facet | S. А. Lazarev N. O. Vartanova A. V. Poddubikov N. A. Mikhailova |
| author_sort | S. А. Lazarev |
| collection | DOAJ |
| description | Scientific relevance. A promising option for dysbiosis correction is the use of metabiotics, products based on metabolites of probiotic microorganisms. During fermentation, Bacillus subtilis bacteria (strains 3H and 1719) produce metabolites that exhibit probiotic properties in vitro. These observations in vitro motivate an in vivo investigation of B. subtilis metabolite effects on colonic mucosal microbiota in mice in experimentally induced dysbiosis and an assessment of the potential of B. subtilis metabolites as metabiotics.Aim. The authors aimed to compare the probiotic activity of B. subtilis 3H and B. subtilis 1719 metabolites and a commercial metabiotic in antibiotic-induced dysbiosis in mice.Materials and methods. The authors induced experimental dysbiosis in BALB/c mice weighing 18–20 g by intraperitoneal injection of gentamicin. For subsequent correction, the test groups received sorbent-bound B. subtilis metabolites, and the comparison group received a commercial metabiotic containing B. subtilis metabolites (VKPM B-2335(3)3) via intragastric injection for 21 days. The quantitative and qualitative analysis of colonic mucosal microbiota included microbial culturing and colony identification by MALDI-TOF mass spectrometry.Results. Antibiotic-induced colonic dysbiosis in mice manifested itself as a decrease in the dominant microbiota and an increase in opportunistic pathogens. After 7 days of metabolite administration, the Lactobacillus population returned to normal in all treatment groups. The mice that received B. subtilis 3H metabolites showed the best results: their Lactobacillus spp. composition corresponded to that of intact animals. The content of Lac+ Escherichia coli returned to 100% in all treatment groups. After 21 days of metabolite administration, the authors observed the elimination of bacteria (Rodentibacter spp., Aerococcus spp.) and fungi (Trichosporon spp., Kazachstania spp.) in the B. subtilis 3H group; Trichosporon spp. (no effect on Kazachstania spp.) in the B. subtilis 1719 group; and Enterococcus spp., Kazachstania spp., and Trichosporon spp. (no effect on Rodentibacter spp. and Aerococcus spp.) in the commercial metabiotic group.Conclusions. Metabolites of B. subtilis strains 3H and 1719 help to restore the diversity and abundance of colonic microbiota in antibiotic-induced dysbiosis. The differences observed in microbiota re-establishment in the treatment groups indicate that there is interstrain variability in the probiotic activity of B. subtilis metabolites. |
| format | Article |
| id | doaj-art-e43f0fb51cec48c7a35d36e515c51a9e |
| institution | Matheson Library |
| issn | 2221-996X 2619-1156 |
| language | Russian |
| publishDate | 2023-10-01 |
| publisher | Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Биопрепараты: Профилактика, диагностика, лечение |
| spelling | doaj-art-e43f0fb51cec48c7a35d36e515c51a9e2025-08-04T10:16:03ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562023-10-01233-143144210.30895/2221-996X-2023-23-445336Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in miceS. А. Lazarev0N. O. Vartanova1A. V. Poddubikov2N. A. Mikhailova3I. Mechnikov Research Institute of Vaccines and SeraI. Mechnikov Research Institute of Vaccines and SeraI. Mechnikov Research Institute of Vaccines and SeraI. Mechnikov Research Institute of Vaccines and SeraScientific relevance. A promising option for dysbiosis correction is the use of metabiotics, products based on metabolites of probiotic microorganisms. During fermentation, Bacillus subtilis bacteria (strains 3H and 1719) produce metabolites that exhibit probiotic properties in vitro. These observations in vitro motivate an in vivo investigation of B. subtilis metabolite effects on colonic mucosal microbiota in mice in experimentally induced dysbiosis and an assessment of the potential of B. subtilis metabolites as metabiotics.Aim. The authors aimed to compare the probiotic activity of B. subtilis 3H and B. subtilis 1719 metabolites and a commercial metabiotic in antibiotic-induced dysbiosis in mice.Materials and methods. The authors induced experimental dysbiosis in BALB/c mice weighing 18–20 g by intraperitoneal injection of gentamicin. For subsequent correction, the test groups received sorbent-bound B. subtilis metabolites, and the comparison group received a commercial metabiotic containing B. subtilis metabolites (VKPM B-2335(3)3) via intragastric injection for 21 days. The quantitative and qualitative analysis of colonic mucosal microbiota included microbial culturing and colony identification by MALDI-TOF mass spectrometry.Results. Antibiotic-induced colonic dysbiosis in mice manifested itself as a decrease in the dominant microbiota and an increase in opportunistic pathogens. After 7 days of metabolite administration, the Lactobacillus population returned to normal in all treatment groups. The mice that received B. subtilis 3H metabolites showed the best results: their Lactobacillus spp. composition corresponded to that of intact animals. The content of Lac+ Escherichia coli returned to 100% in all treatment groups. After 21 days of metabolite administration, the authors observed the elimination of bacteria (Rodentibacter spp., Aerococcus spp.) and fungi (Trichosporon spp., Kazachstania spp.) in the B. subtilis 3H group; Trichosporon spp. (no effect on Kazachstania spp.) in the B. subtilis 1719 group; and Enterococcus spp., Kazachstania spp., and Trichosporon spp. (no effect on Rodentibacter spp. and Aerococcus spp.) in the commercial metabiotic group.Conclusions. Metabolites of B. subtilis strains 3H and 1719 help to restore the diversity and abundance of colonic microbiota in antibiotic-induced dysbiosis. The differences observed in microbiota re-establishment in the treatment groups indicate that there is interstrain variability in the probiotic activity of B. subtilis metabolites.https://www.biopreparations.ru/jour/article/view/445<i>bacillus subtilis</i> 3h<i>bacillus subtilis</i> 1719<i>b. subtilis</i> metabolitesantibiotic-induced dysbiosisdysbiosis correctionintestinal dysbiosismetabioticsmucosal microbiota |
| spellingShingle | S. А. Lazarev N. O. Vartanova A. V. Poddubikov N. A. Mikhailova Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice Биопрепараты: Профилактика, диагностика, лечение <i>bacillus subtilis</i> 3h <i>bacillus subtilis</i> 1719 <i>b. subtilis</i> metabolites antibiotic-induced dysbiosis dysbiosis correction intestinal dysbiosis metabiotics mucosal microbiota |
| title | Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice |
| title_full | Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice |
| title_fullStr | Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice |
| title_full_unstemmed | Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice |
| title_short | Probiotic activity of <i>Bacillus subtilis</i> metabolites in experimentally induced dysbiosis in mice |
| title_sort | probiotic activity of i bacillus subtilis i metabolites in experimentally induced dysbiosis in mice |
| topic | <i>bacillus subtilis</i> 3h <i>bacillus subtilis</i> 1719 <i>b. subtilis</i> metabolites antibiotic-induced dysbiosis dysbiosis correction intestinal dysbiosis metabiotics mucosal microbiota |
| url | https://www.biopreparations.ru/jour/article/view/445 |
| work_keys_str_mv | AT salazarev probioticactivityofibacillussubtilisimetabolitesinexperimentallyinduceddysbiosisinmice AT novartanova probioticactivityofibacillussubtilisimetabolitesinexperimentallyinduceddysbiosisinmice AT avpoddubikov probioticactivityofibacillussubtilisimetabolitesinexperimentallyinduceddysbiosisinmice AT namikhailova probioticactivityofibacillussubtilisimetabolitesinexperimentallyinduceddysbiosisinmice |